Literature DB >> 19862564

Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas.

Nunung Nur Rahmah1, Keiichi Sakai, Jun Nakayama, Kazuhiro Hongo.   

Abstract

Prognosis of chordomas is difficult to predict based solely on histological findings. The purpose of this study was to assess expressions of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and matrix metalloproteinase (MMP)-2, MMP-9 in skull base chordomas and to find out their correlations to outcome. Immunohistochemical study was performed in 19 samples (initial, n = 11; recurrent, n = 8) from 11 patients. The correlations among expression of RECK, MMP-2, MMP-9, and their prognostic values were analyzed. Significant correlation between RECK and MMP-9 was found, but there was no correlation found between MMP-2 and MMP-9. Higher MMP-9 expression significantly influenced outcome. Furthermore, MMP-9/RECK ratio showed significant correlation to outcome, showing their inverse relationship in the disease progress of skull base chordoma. RECK and MMP-9 can be valuable markers to predict prognosis in skull base chordomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19862564     DOI: 10.1007/s10143-009-0228-y

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  28 in total

1.  Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis.

Authors:  H Kawamoto; K Kawamoto; T Mizoue; T Uozumi; K Arita; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

2.  Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas.

Authors:  Aly G Saad; Margaret H Collins
Journal:  Pediatr Dev Pathol       Date:  2005-07-14

3.  The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.

Authors:  J Oh; R Takahashi; S Kondo; A Mizoguchi; E Adachi; R M Sasahara; S Nishimura; Y Imamura; H Kitayama; D B Alexander; C Ide; T P Horan; T Arakawa; H Yoshida; S Nishikawa; Y Itoh; M Seiki; S Itohara; C Takahashi; M Noda
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

4.  Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive?

Authors:  S Yokoyama; H Hirano; K Moroki; M Goto; S Imamura; J I Kuratsu
Journal:  Neurosurgery       Date:  2001-10       Impact factor: 4.654

5.  Cadherins and catenins in clival chordomas: correlation of expression with tumor aggressiveness.

Authors:  Aymara Triana; Chandranath Sen; David Wolfe; Rachel Hazan
Journal:  Am J Surg Pathol       Date:  2005-11       Impact factor: 6.394

6.  Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas.

Authors:  Kyoko Komatsu; Yoko Nakanishi; Norimichi Nemoto; Tomokatsu Hori; Tatsuo Sawada; Makio Kobayashi
Journal:  Brain Tumor Pathol       Date:  2004       Impact factor: 3.298

Review 7.  RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.

Authors:  Jonathan C M Clark; David M Thomas; Peter F M Choong; Crispin R Dass
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

8.  Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.

Authors:  Paul N Span; C G J Sweep; Peggy Manders; Louk V A M Beex; David Leppert; Raija L P Lindberg
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

9.  Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients.

Authors:  E Gay; L N Sekhar; E Rubinstein; D C Wright; C Sen; I P Janecka; C H Snyderman
Journal:  Neurosurgery       Date:  1995-05       Impact factor: 4.654

10.  Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.

Authors:  Ulrich J Knappe; Christian Hagel; Björn W Lisboa; Waldemar Wilczak; Dieter K Lüdecke; Wolfgang Saeger
Journal:  Acta Neuropathol       Date:  2003-08-02       Impact factor: 17.088

View more
  3 in total

1.  Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions.

Authors:  Nunung Nur Rahmah; Keiichi Sakai; Kenji Sano; Kazuhiro Hongo
Journal:  J Neurooncol       Date:  2011-12-20       Impact factor: 4.130

2.  Potential Role of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Regulation of Matrix Metalloproteinases (MMPs) Expression in Periodontal Diseases.

Authors:  Nian Liu; Bin Zhou; Guangxun Zhu
Journal:  Med Sci Monit       Date:  2016-06-07

3.  Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.

Authors:  Franco Rubino; Christopher Alvarez-Breckenridge; Kadir Akdemir; Anthony P Conley; Andrew J Bishop; Wei-Lien Wang; Alexander J Lazar; Laurence D Rhines; Franco DeMonte; Shaan M Raza
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.